Stocktube video
30/03/2012

Alliance Pharma CEO looks forward to continued good growth prospects

View full size
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: APH
Latest Price: 28.75p  (0,00%)
52-week High: 37.13p
52-week Low: 26.25p
Market Cap: 69.17M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Alliance Pharma
www.alliancepharma.co.uk

Alliance Pharma plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development, marketing and distribution of pharmaceutical products. Its brands include Nu-Seals, Forceval, Hydromol, Deltacortril, Symmetrel, Syntocinon, Naseptin, Syntometrine, Synacthen and Slow-K.

Pdf

Alliance Pharma acquires Quinoderm and Ceanel brands for £1.5 mln

19th Dec 2011, 8:01 am by Jamie Ashcroft Alliance will acquire the Quinoderm and Ceanel brands for £1.5 million

Alliance Pharma (LON:APH) has expanded its product portfolio with the acquisition of two skin care brands.

This morning it revealed the deal to acquire the Quinoderm and Ceanel brands from Ferndale Pharmaceuticals Ltd for £1.5m in cash. Quinoderm is a treatment for acne and Ceanel is a shampoo treatment for scalp psoriasis. 

The two brands contributed sales of £600,000 in the twelve months to September 30 2011.

"We are delighted to announce this acquisition, which extends our Dermatology portfolio.  Quinoderm complements our existing product Rizuderm (isotretinoin), a treatment for severe acne acquired in September this year,” said chief executive John Dawson.

"Today's acquisition, which represents our third transaction this year, is expected to be earnings enhancing in 2012. We continue to evaluate further opportunities to broaden our product portfolio."

The deal is being funded via a £20 million revolving credit facility which was set up last November. 

The facility was established to support the group’s acquisition strategy. Today it said that £6.5 million of the facility has now been used.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.